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1 Drug description 
Generic/Brand name/ATC code:  
Paclitaxel/Abraxane®/L01CD01 
Developer/Company:  
Celgene Corporation 
Description:  
Paclitaxel, a natural mitotic inhibitor, belongs to the family of taxanes and is 
obtained via a semi-synthetic process from Taxus baccata, a conifer. It is 
used as cancer chemotherapy by targeting tubulin. It stabilises the microtu-
bule polymer and protects it from disassembly. Thereby the chromosomes 
are unable to achieve a metaphase spindle configuration that blocks the pro-
gression of mitosis. This blockade triggers apoptosis or the reversion to the 
G-phase of the cell cycle without cell division [1, 2]. Abraxane® is the albu-
min-bound formulation of paclitaxel (nab-paclitaxel) which was designed to 
overcome the insolubility problems associated with conventional paclitaxel 
formulations [3].  
The drug is administered intravenously as an infusion over 30-40 minutes. 
For the treatment of pancreatic cancer an Abraxane® dose of 125 mg/m2 of 
body surface is suggested. Patients use the drug on days 1, 8 and 15 of each 
28-day cycle. Gemcitabine is administered immediately after Abraxane® on 
the same days. The therapy should be continued until the disease progresses 
or toxicity gets intolerable [4].  
 
2 Indication 
Patients with metastatic adenocarcinoma of the pancreas who have not re-
ceived prior therapy for their metastatic disease. 
 
3 Current regulatory status 
In the European Union and the USA, paclitaxel monotherapy is licensed for 
second-line therapy for metastatic breast cancer [5-8]. In the USA, the drug 
is also approved in combination with carboplatin for the first-line treatment 
of non-small cell lung cancer [9]. 
In September 2013, the U.S. Food and Drug Administration (FDA) author-
ised nab-paclitaxel in combination with gemcitabine for the first-line treat-
ment of patients with metastatic pancreatic cancer [10]. This new indication 
for Abraxane® was assessed under the agency’s priority review programme. 
In addition, orphan product designation was granted for pancreatic cancer 
[11, 12].  
In November 2013, the European Medicines Agency’s Committee for Medic-
inal Products for Human Use (CHMP) recommended nab-paclitaxel in 
combination with gemcitabine for the use in patients with metastatic pan-
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creatic cancer [13]. Accordingly, the European Commission has amended 
the marketing authorisation in December 2013 [14, 15]. In 2010, the Euro-
pean Commission granted an orphan designation for nanoparticle albumin-
bound paclitaxel for the treatment of pancreatic cancer which was with-
drawn from the Community Register of designated Orphan Medicinal 
Products at the sponsor’s request in February 2013 [16]. 
 
4 Burden of disease 
In 2008, about 340,000 people were diagnosed with pancreatic cancer world-
wide with over 330,000 patients dying from this disease. Highest incidence 
rates are found in North America and Western Europe [17]. In these parts of 
the world pancreatic cancer is the fourth most frequent cause of cancer-
related death [18, 19]. This holds also true for Austria, where 1,424 men and 
women died of pancreatic cancer in 2009 although it only accounts for 4% of 
all cancers diagnosed [20]. This is attributable to the high lethality and the 
poor prognosis of the disease. Men are more frequently affected than wom-
en. Per 100,000 people in Austria, 10.3 men and 7.6 women were diagnosed 
with pancreatic cancer in 2009 [20]. 8 out of 10 pancreatic cancers occur in 
patients 60 years or older [21].  
Risk factors for the development of pancreatic cancer include cigarette 
smoking, chronic pancreatitis, family history, obesity, type 1 and type 2 dia-
betes mellitus and processed meat [21, 22]. In the UK, smoking causes over 
25% of pancreatic cancers and smokeless tobacco increases the risk further. 
In people with diabetes mellitus type I or II the risk of pancreatic cancer ap-
proximately doubles. Inflammatory diseases of the pancreas increase the 
risk as well as a family history of pancreatic cancer. Overweight and obesity 
cause about 1,000 pancreatic cancer cases in the UK every year and pro-
cessed meat may also raise the pancreatic cancer risk [21]. 
The seventh edition of the tumour node metastasis (TNM) system classifies 
pancreatic cancer into the stages Ia, Ib, IIa, IIb, III and IV. The division is 
based on the size of the primary tumour (T), the affection of lymph nodes 
(N) and the presence of distant metastases (M). Stages Ia and Ib describe 
tumours limited to the pancreas with ≤ 2 and > 2 cm in the greatest dimen-
sion, respectively. Local lymph node metastases or distant metastases are ab-
sent. Stage IIa tumours extend beyond the pancreas without affecting the ce-
liac axis or the superior mesenteric artery. Lymph nodes and other body 
parts are still not involved. Stage IIb describes tumours of different sizes 
with regional lymph node metastases. Stage III tumours are no longer resec-
table and stage IV tumours finally include distant metastases [22]. 
Since pancreatic cancer generally does not cause early symptoms, cancers 
are usually diagnosed at advanced stages and are thus highly lethal [20]. 
Prognosis depends on whether tumours are located and fully resectable or 
have already spread to other body parts. The former stage has the best prog-
nosis and is present in less than 20% of patients. The median survival time 
of patients with metastatic pancreatic cancer is about 6 months [18]. Pa-
tients with completely resectable small tumours and no lymph node metas-
tases have a 5-year survival rate of 18% to 24% [22]. Among patients with 
metastatic disease, the 5-year survival rate is only 2% [18]. A further prog-
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nostic factor is age, where younger patients are more likely to survive than 
older ones [21]. 
 
5 Current treatment 
Therapies for stage I and stage II pancreatic cancer include surgery and 
post-operative chemotherapy. The more advanced stages of pancreatic can-
cer, i.e. stage III or higher, are incurable. The primary treatment modality 
for patients with locally advanced cancer is chemotherapy with gemcitabine 
at conventional dosing (1000 mg/m2 over 30 min) [22, 23]. 
The preferred treatment of metastatic (stage IV) pancreatic cancer in eligi-
ble patients is chemotherapy. In addition, all patients are eligible for pallia-
tive treatment. 
 Palliative therapy: Palliative therapy focuses on pain-relieving 
techniques like celiac or intrapleural blocks and supportive care. 
Surgical procedures include biliary bypass surgery, percutaneous 
radiologic biliary stent placement or endoscopically placed biliary 
stents. 
 Chemotherapy: Gemcitabine alone or in combination with other 
agents or a chemotherapy regimen consisting of folinic acid, 5-FU, 
irinotecan and oxaliplatin (FOLFIRINOX) are used in chemother-
apy. In general, existing therapies with gemcitabine alone or in 
combination with erlotinib show low response rates and do not suf-
ficiently improve survival in patients with metastatic pancreatic 
cancer.  
o Nevertheless, based on the results of phase II and phase III 
clinical trials, single-agent therapy with gemcitabine was 
standard first-line chemotherapy until recently [23], espe-
cially for patients with poor performance status (ECOG  
2) [24, 25].  
o Patients may also be treated with a combination of gem-
citabine and erlotinib, but the actual benefit might be ra-
ther small and is limited to patients who develop skin rash 
within the first 8 weeks of treatment [23,25]. 
o For patients with good performance status, (i.e. ECOG 0 
or 1 or a corresponding Karnofsky performance-status 
score of 70 or more [26]), the following combination 
chemotherapies are recommended as first-line therapy 
[25]: 
FOLFIRINOX showed a significantly prolonged survival 
in comparison to gemcitabine. Median overall survival was 
11.1 months versus 6.8 months and the response rate was 
31.6% versus 9.4%, but at the cost of more adverse events 
in the FOLFIRINOX group [24]. The same study investi-
gated only patients aged 75 years and younger, with an ad-
equate liver function (i.e. bilirubin ≤ 1.5 times the upper 
surgery and post-
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limit of the normal range). Therefore this therapy regimen 
is only suitable for this limited patient group. 
o As an alternative to FOLFIRINOX, a combination of gem-
citabine plus nab-paclitaxel is recommended for patients 
with a bilirubin level within the normal range. [24]. 
 
o Combinations of gemcitabine and other cytotoxic agents, 
such as 5-FU or capecitabine, irinotecan, cis- or oxali-
platin, did not show any significant advantage in survival 
even in large randomised controlled trials (RCTs) and 
therefore are not recommended as first-line treatment of 
metastatic pancreatic cancer [23].  
There is no widely accepted standard of care for patients who have failed 
gemcitabine-containing chemotherapy [24]. The only data indicating a sur-
vival benefit for second-line therapy come from a study comparing 5-FU, 
leucovorin and oxaliplatin (OFF regimen) versus best supportive care. The 
median survival was 4.82 months versus 2.30 months in favour of the OFF 
treatment. Since this study had a very small number of participants and 
closed early, the evidence for this effect appears to be rather weak [22]. 
 
6 Evidence 
A systematic literature search was conducted on the 16th of January 2014 in 
the medical databases Ovid Medline, EMBASE, the Cochrane Library and 
the databases of the Centre for Review and Dissemination (CRD), resulting 
in 343 records. Of those, 12 records reporting results of 1 phase III trial [27-
33] and 3 phase I/II trials [34-38] were included. 
In addition, a hand search was performed including reference lists of topic-
related reviews or articles, a free web search as well as the EMA and the 
FDA websites. This resulted in 3 additional relevant conference abstracts 
[39-41]. No further relevant articles or conference abstracts were found 
among the material that the manufacturer had sent on request.  
In summary, 3 full-text publications and 12 conference abstracts reporting 
on one phase III trial [27-33, 39-41] and 3 phase I/II trials [34-38] were in-
cluded. 
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6.1 Efficacy and safety – phase III studies 
Table 1: Summary of efficacy 
Study title  
A randomised phase III study of weekly ABI-007 plus gemcitabine versus gemcitabine alone in patients 
with metastatic adenocarcinoma of the pancreas (MPACT) [27, 40] 
Study  
identifier 
NCT00844649, EudraCT 2009-011305-17 
Design Randomised controlled, open-label, international, multicentre trial; 
N = 861 (431 vs 430); 
allocation randomly (1:1 ratio) to nab-paclitaxel plus gemcitabine or gemcitabine 
alone; stratified by geographic region, Karnofsky performance status and by the 
presence of liver metastases 
Duration  Enrolment: NR 
Median follow-up: NR 
(Maximum time in follow-up was 37 months) 
Cut-off date for analysis: 17 September 2012 
Hypothesis Superiority 
Funding Celgene Corporation 
Treatment groups Intervention 
(n=431) 
Nab-paclitaxel 125 mg/m2, 30 to 40 minutes IV; 
Gemcitabine 1000 mg/m2 IV; 
Cycle 1: on days 1, 8, 15, 29, 36 and 43, subsequent cycles: on 
days 1, 8 and 15 every 4 weeks. 
Control 
(n=430) 
Gemcitabine 1000 mg/m2 IV; 
Cycle 1: weekly for 7 of 8 weeks, subsequent cycles: on days 1, 
8 and 15 every 4 weeks. 
Endpoints and 
definitions 
Overall survival 
(primary 
efficacy 
outcome) 
OS Time from randomisation to death due to any cause. 
Progression-free 
survival 
(secondary 
outcome) 
PFS Time from the date of randomisation to the date of 
disease progression or death (any cause) on or prior 
to the clinical cut-off date, whichever occurred 
earlier. 
Assessed by independent radiological review (IRR) 
Overall response 
rate (secondary 
outcome) 
ORR Percentage of participants who achieved a 
confirmed complete (CR) or partial response (PR) 
based on an independent blinded radiologic review 
(IRR) assessment of response using Response 
Evaluation Criteria in Solid Tumors (RECIST) 
guidelines 
Treatment-
related adverse 
event 
TRAE Graded according to the National Cancer Institute 
Common Terminology Criteria for Adverse Events, 
version 3.0 (CTC version 3.0) 
Disease control 
rate 
DCR Percentage of participants with stable disease for 
≥16 weeks 
Complete 
response 
CR Disappearance of all known disease sites and no new 
sites or disease-related symptoms confirmed at least 
4 weeks after initial documentation 
Partial response PR At least a 30% decrease in the sum of the longest 
diameters of target lesions and no progression in 
non-target lesions 
Stable disease SD NR 
Horizon Scanning in Oncology 
8 LBI-HTA | 2014 
Results and analysis 
Analysis  
description 
ITT-analysis; 
Primary endpoint: OS analysed with the use of Kaplan-Meier method and a 
stratified log-rank test; Sample size: 842 patients were needed to observe 608 OS 
events with a statistical power of 90% to detect a hazard ratio for death with nab-
paclitaxel plus gemcitabine versus gemcitabine monotherapy of 0.769 at a two-
sided αlevel of 0.049. 
Analysis  
population 
Inclusion  adults at least 18 years of age 
 histologically or cytologically confirmed metastatic 
adenocarcinoma of the pancreas, measurable according to 
RECIST 1.0 criteria 
 initial diagnosis of metastatic disease must have occurred 
within 6 weeks before randomisation 
 no previous chemotherapy for metastatic disease  
 Karnofsky performance-status score ≥70 (on a scale from 0 to 
100, with higher scores indicating better performance status) 
Exclusion  Cytotoxic doses of gemcitabine or any other chemotherapy in 
the adjuvant setting 
 Islet-cell neoplasms 
 Locally advanced disease 
 Haemoglobin level <9 g per dl 
 Absolute neutrophil count <1.5x109 per litre 
 Bilirubin level above upper limit of normal range 
Characteristics Median age (years): 62 (27–86) vs 63 (32–88) 
Female (%): 43 vs 40 
Ethnicity_White/Black/Asian/Hispanic/Others (%): 88/4/2/6/1 vs 
87/4/2/6/1 
Karnofsky performance status score_100/90/80/70/60 (%): 
16/42/35/7/<1 vs 16/46/30/8/0 
Pancreatic tumour location_head/body/tail/unknown (%): 
44/31/24/1 vs 42/32/26/1 
Site of metastatic disease_liver/lung/peritoneum (%): 85/35/4 vs 
84/43/2 
No. of metastatic sites_1/2/3/>3 (%): 8/47/32/14 vs 5/48/33/15 
Results (main 
analysis 17 
September 2012) 
Treatment group Gemcitabine  Nab-Paclitaxel + 
Gemcitabine 
Number of subjects N=430 N=431 
OS (months) 
median 
95% CI 
 
6.7 
6.0–7.2 
 
8.5 
7.9–9.5 
12 months survival rate 
(%) 
95% CI 
22 
18–27 
35 
30–39 
24 months survival rate 
(%) 
95% CI 
4 
2–7 
9 
6–13 
PFS (months) 
median 
95% CI 
 
3.7 
3.6–4.0 
 
5.5 
4.5–5.9 
ORR (%) 
95% CI 
7 
5.0–10.1 
23 
19.1–27.2 
DCR (%) 
95% CI 
33 
28–37 
48 
43–53 
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CR 
No of patients (%) 
 
0 
 
1 (<1) 
PR 
No of patients (%) 
 
31 (7) 
 
98 (23) 
SD 
No of patients (%) 
 
122 (28) 
 
118 (27) 
Results (post-hoc up-
date analysis 1 April 
2013) 
OS (months) 
median 
95% CI 
 
6.6 
NR 
 
8.7 
NR 
24 months survival rate 
(%) 
95% CI 
5 
NR 
10 
NR 
36 months survival rate 
(%) 
95% CI 
0 
NR 
4 
NR 
Effect estimate 
per comparison 
(main analysis 17 
September 2012) 
Comparison groups  Nab-Paclitaxel + 
Gemcitabine vs 
Gemcitabine 
OS HR 0.72 
95% CI 0.62–0.83 
P value  <0.001 
12 months survival rate Effect estimate NR 
95% CI NR 
P value <0.001 
24 months survival rate Effect estimate NR 
95% CI NR 
P value 0.02 
PFS HR 0.69 
95% CI 0.58–0.82 
P value <0.001 
ORR (independent review) HR 3.19 
95% CI 2.18 4.66 
P value  <0.001 
RDC HR 1.46 
95% CI 1.23–1.72 
P value  <0.001 
Effect estimate 
per comparison 
(post-hoc update 
analysis 1 April 
2013) 
OS HR 0.72 
95% CI 0.62–0.83 
P value  <0.001 
Abbreviations: AE = adverse event, CR = complete response, CI = confidence interval, DD = participants with dose delays/doses 
not given, DI = participants with dose interruptions, DR = participants with dose reductions, HR = hazard ratio, IRR = inde-
pendent radiological review, ITT = intent to treat, IV…intravenous, NR = not reported, ORR = overall response rate, OS = 
overall survival, PFS = progression-free survival, PR = partial response, RDC = rate of disease control, RECIST = Response 
Evaluation Criteria in Solid Tumors, SD = stable disease, TRAE = treatment-related adverse event 
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Table 2: Common adverse events 
MPACT (NCT00844649)  
Grade (according  
to CTC version 
3.0) Outcome [n (%)] 
Nab-Paclitaxel + Gemcitabine 
(n=421) 
Gemcitabine 
(n=402) 
Adverse event leading to death 18 (4) 18 (4) 
All grades Fatigue 248 (59) 183 (46) 
Peripheral oedema 194 (46) 122 (30) 
Pyrexia 171 (41) 114 (28) 
Asthenia 79 (19) 54 (13) 
Mucositis 42 (10) 16 (4) 
Nausea 228 (54) 192 (48) 
Diarrhoea 184 (44) 95 (24) 
Vomiting 151 (36) 113 (28) 
Alopecia 212 (50) 21 (5) 
Rash 128 (30) 45 (11) 
Peripheral neuropathy 227 (54) 51 (13) 
Dysgeusia 68 (16) 33 (8) 
Headache 60 (14) 38 (9) 
Decreased appetite 152 (36) 104 (26) 
Dehydration 87 (21) 45 (11) 
Hypokalaemia 52 (12) 28 (7) 
Cough 72 (17) 30 (7) 
Epistaxis 64 (15) 14 (3) 
Urinary tract infections 47 (11) 20 (5) 
Pain in extremity 48 (11) 24 (6) 
Arthralgia 47 (11) 13 (3) 
Myalgia 44 (10) 15 (4) 
Depression 51 (12) 24 (6) 
Grade 1–4 Neutropenia NR (73) NR (58) 
Thrombocytopenia NR (74) NR (70) 
Grade ≥3 Fatigue 77 (18) 37 (9) 
Peripheral oedema 13 (3) 12 (3) 
Pyrexia 12 (3) 4 (1) 
Asthenia 29 (7) 17 (4) 
Mucositis 6 (1) 1 (<1) 
Nausea 27 (6) 14 (3) 
Diarrhoea 26 (6) 6 (1) 
Vomiting 25 (6) 15 (4) 
Alopecia 6 (1) 0 
Rash 8 (2) 2 (<1) 
Peripheral neuropathy 70 (17) 3 (1) 
Dysgeusia 0 0 
Headache 1 (<1) 1 (<1) 
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Decreased appetite 23 (5) 8 (2) 
Dehydration 31 (7) 10 (2) 
Hypokalaemia 18 (4) 6 (1) 
Cough 0 0 
Epistaxis 1 (<1) 1 (<1) 
Urinary tract infections 10 (2) 1 (<1) 
Pain in extremity 3 (1) 3 (1) 
Arthralgia 3 (1) 1 (<1) 
Myalgia 4 (1) 0 
Depression 1 (<1) 0 
Neutropenia [n/N] 153/405 (38) 103/388 (27) 
Leukopenia [n/N] 124/405 (31) 63/388 (16) 
Thrombocytopenia [n/N] 52/405 (13) 36/388 (9) 
Anaemia [n/N] 53/405 (13) 48/388 (12) 
Abbreviations: CTC = Common Terminology Criteria 
 
The MPACT trial, an international, multicentre, open-label phase III ran-
domised controlled trial (RCT), conducted in the European Union, North 
America and Australia, investigated the efficacy and safety of nab-paclitaxel 
plus gemcitabine in comparison to gemcitabine alone as first-line treatment 
of metastatic adenocarcinoma of the pancreas [27]. The primary efficacy end 
point was overall survival (OS). Additional end points were progression-free 
survival (PFS), overall response rate (ORR) – both assessed by independent 
radiographic review – and treatment-related adverse events (TRAE). 
To be included, patients had to have a histologically or cytologically con-
firmed metastatic disease according to RECIST version 1.0, a Karnofsky per-
formance-status score of 70 or more and had to not have previously received 
chemotherapy for their metastatic disease. 861 patients were randomly as-
signed in a 1:1 ratio to the intervention group or the control arm. Randomi-
sation was stratified by geographic region, Karnofsky performance status 
and by the presence of liver metastases. Patients in the intervention group 
received a 30–40-minute intravenous (IV) infusion of nab-paclitaxel 125 
mg/m2 followed by gemcitabine 1000 mg/m2 IV on days 1, 8 and 15 of each 
28-day cycle. Patients in the control group received gemcitabine alone 1000 
mg/m2 IV weekly for 7 of 8 weeks in cycle 1, and 1000 mg/m2 on days 1, 8 
and 15 of each subsequent 28-day cycle. In both groups treatment was con-
tinued until disease progression or unacceptable toxicity. Crossover was not 
allowed at any time after randomisation.  
The mean age in the study population was 63 years. The majority of patients 
were Caucasian (87%), 58% were men and 60% had a Karnofsky perfor-
mance status score of 90 or 100. Regarding disease characteristics, 93% of 
the patients had two or more metastatic sites and 84% had liver metastases. 
international, 
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In the final analysis at the data-cutoff date (17 September 2012), 333 (77%) 
of patients treated with nab-paclitaxel plus gemcitabine and 359 (83%) pa-
tients treated with gemcitabine alone had died. In the ITT population the 
median OS was 8.5 months in the intervention group and 6.7 months in the 
control group, showing a statistically significant improvement in favour of 
the intervention group (HR for death 0.72 (95% CI 0.62–0.83; p<0.001)). 
There were also statistically significant higher 1-year and 2-year survival 
rates for the nab-paclitaxel plus gemcitabine group with 35% vs 22% 
(p<0.001) and 9% vs 4% (p=0.02) respectively. An updated post-hoc OS 
analysis on 1 April 2013 reported that at this date, 380 (88%) patients of the 
nab-paclitaxel plus gemcitabine group and 394 (92%) patients of the gem-
citabine-alone group had died and the statistically significant difference in 
OS remained unchanged in this analysis [40]. Due to the longer follow-up an 
estimate of the 3-year survival rates was possible, which was 4% in the inter-
vention group and 0% in the control group. 
For the secondary efficacy endpoint, the main analysis at data-cutoff date 
showed a statistically significant longer median PFS in the intervention 
group as determined per independent radiographic review (nab-paclitaxel 
plus gemcitabine 5.5 months vs gemcitabine alone 3.7 months, HR 0.69 
(95% CI 0.58–0.82, p<0.001)). In addition, ORR was significantly better in 
the nab-paclitaxel plus gemcitabine group (23% vs 7%, HR 3.19 (95% CI 
2.18–4.66, p<0.001), with all but one person in the intervention group being 
partial responses (PR). 
Subgroup analyses for OS and PFS showed a significant benefit of nab-
paclitaxel plus gemcitabine for most of the predefined subgroups, but it is 
not reported if there were differences in the magnitude of the effect between 
these subgroups. 
In general, the majority of the adverse events (AEs) in both groups were of 
lower grade and all of them occurred more often in the intervention group 
(see table 2). The most frequent AEs of grade 3 or higher were neutropenia 
(nab-paclitaxel plus gemcitabine 38% vs gemcitabine alone 27%), leukope-
nia (nab-paclitaxel plus gemcitabine 31% vs gemcitabine alone 16%), fa-
tigue (nab-paclitaxel plus gemcitabine 17% vs gemcitabine alone 7%) and 
peripheral neuropathy (nab-paclitaxel plus gemcitabine 17% vs gemcitabine 
alone 1%). The median time to first occurrence of peripheral neuropathy 
grade 3 or higher was 140 days in the intervention group and the median 
time to improvement from grade 3 to grade ≤ 1 was 29 days [4, 27].  
There was no significant difference in serious AEs (50% vs 43%) and AEs 
leading to death between the two treatment groups (4% vs 4%) [27], but 20% 
in the nab-paclitaxel plus gemcitabine group discontinued treatment due to 
unacceptable toxicities compared to only 7% in the gemcitabine-alone group 
[42]. 
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6.2 Efficacy and safety – further studies 
An open-label phase I/II dose-finding study in 4 centres in the USA investi-
gated the maximum-tolerated dose (MTD) of first-line treatment with gem-
citabine plus nab-paclitaxel in metastatic pancreatic adenocarcinoma and 
also provided efficacy and safety data [34-36]. 67 patients were treated with 
100, 125 or 150 mg/m2 nab-paclitaxel followed by gemcitabine 1,000 mg/m2 
on days 1, 8 and 15 every 28 days. The MTD was 1,000 mg/m2 of gemcita-
bine plus 125 mg/m2 of nab-paclitaxel once a week for 3 weeks, every 28 
days. For all 67 patients, the median PFS was 7.1 months (95% CI 5.7–8.0 
months) and median OS was 10.3 months (95% CI 8.4–13.6). The ORR was 
46%, with 3 patients (4%) having complete responses. Analysis including 
only patients treated at the MTD (n=44) resulted in a median PFS of 7.9 
months (95% CI 5.8–11.0 months) and a median OS of 12.2 months (95% CI 
8.9–17.9 months). One patient in the 150 mg/m2 nab-paclitaxel group died 
due to sepsis. The most common treatment-related AEs of grade ≥ 3 were 
neutropenia (67%), leukopenia (44%), thrombocytopenia (23%), fatigue 
(21%) and sensory neuropathy (15%). 
There was another open-label phase I/II dose-finding study, conducted in 
China, which investigated the MTD and the dose limiting toxicities (DLT) 
of induction treatment with nab-paclitaxel plus gemcitabine in patients with 
metastatic pancreas carcinoma [37]. 21 patients received nab-paclitaxel at 
the dose levels of 80 mg/m2, 100 mg/m2 and 120 mg/m2, followed by gem-
citabine (1,000 mg/m2) on days 1 and 8, and repeated every 21 days. MTD 
was not met in this study. Median PFS was 4.4 months (95% CI 4.0–4.8 
months) and median OS was 12.2 months (95% CI 9.5–14.8 months), with a 
1-year survival rate of 65%. The ORR rate in this study was 28.6%, with all 
of them being partial responses. Most frequent treatment-related grade ≥ 3 
AEs were the neutropenia (9.5%), febrile neutropenia (4.8%), thrombocyto-
penia (4.8%) and sensory neuropathy (4.8%). 
One conference abstract publication reported an interim analysis of a single-
arm phase II study of first-line therapy with gemcitabine and nab-paclitaxel 
followed by consolidation with FOLFIRINOX [38], but no fully published 
results are available.  
 
7 Estimated costs 
In Austria, the price for a 100 mg vial of Abraxane® is € 369.75 [43]. Admin-
istered as first-line therapy for metastatic pancreas carcinoma, the recom-
mended treatment regimen is 125 mg/m2 on days 1, 8 and 15 of a 28-day cy-
cle. With an average body surface area of 1.73 m2, this results in costs of 
€ 2,398 per treatment cycle. As nab-paclitaxel is given in combination with 
gemcitabine 1000 mg/m2, these costs accrue in addition to € 1,278 for the 
gemcitabine treatment for 3 days assuming that 2 vials are needed on each of 
the 3 days (€ 213.05 for 1000 mg vial).  
In the MPACT trial, the mean duration of treatment in the intervention 
group was 3.9 months, resulting in a median cumulative dose of 1,425 
mg/m2 for Abraxane® and of 11,400 mg/m2 for gemcitabine [31]. Therefore 
the costs for a whole treatment period would be € 9,115 for Abraxane® and € 
4,202 for gemcitabine respectively. 
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8 Ongoing research 
A search in the databases ClinicalTrials.gov and cinicaltrialsregister.eu 
yielded only one ongoing phase III trial investigating paclitaxel as first-line 
therapy for patients with metastatic pancreas carcinoma, which is an obser-
vational follow-up study of the MPACT trial (NCT00844649, EudraCT: 
2009-011305-17), of which results are presented in this report: 
 NCT02021500: MPACT extension study: Multicentre, survival data 
collection in subjects previously enrolled in protocol CA046. The 
completion of the study is planned for March 2015. 
In addition to this study, there are 3 ongoing phase III trials investigating 
paclitaxel in combination with chemotherapy or radiation therapy for pa-
tients with locally advanced or resected pancreas carcinoma.  
 NCT01836432: Immunotherapy study in borderline resectable or lo-
cally advanced unresectable pancreatic cancer. The completion of the 
study is planned for June 2017. 
 NCT02024009: Systemic therapy and chemoradiation in advanced lo-
calised pancreatic cancer – 2. The completion of the study is planned 
for September 2019. 
 NCT01964430: Study to compare disease-free survival of subjects 
with surgically resected pancreatic cancer in the adjuvant setting who 
are taking nab-paclitaxel in combination with gemcitabine vs gem-
citabine alone. The completion of the study is planned for October 
2020. 
In addition, 12 ongoing phase II trials for combination therapies including 
paclitaxel in patients with metastatic pancreas carcinoma and more than 100 
ongoing phase III/IV studies evaluating paclitaxel in a broad variety of indi-
cations such as breast cancer, non-small cell lung cancer, gastric cancer or 
ovarian cancer were found. 
 
9 Commentary 
Pancreatic cancer is the 4th leading cause of cancer-related death in North 
America and Western Europe [18, 19]. Since it does not cause early symp-
toms, cancers are often diagnosed in advanced stages and are highly lethal 
with a 5-year survival rate of only 2% for metastatic disease [18]. Beside pal-
liative care, chemotherapy with gemcitabine is the standard first-line treat-
ment for metastatic pancreas carcinoma, but it shows low response rates and 
does not sufficiently improve survival [22]. Therefore the clinical need for 
new treatment options is high, which is also indicated by assessing Abrax-
ane® under the FDA’s priority review programme [11, 12]. 
Based on the results of one phase III RCT, the FDA and the European 
Commission have now approved nab-paclitaxel (Abraxane®) in combination 
with gemcitabine as first-line treatment for patients with metastatic pancre-
as carcinoma [10,14,15]. 
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In this study (MPACT) [27], nab-paclitaxel plus gemcitabine was compared 
to gemcitabine alone in 861 patients previously not treated for their meta-
static disease. At the data-cutoff date on 17 September 2012, a statistically 
significant improvement in OS (8.5 vs 6.7 months), PFS (5.5 vs 3.7 months) 
and ORR (23 vs 7%) was reported. An updated survival analysis on 1 April 
2013 showed a 2-year survival rate of 9% vs 4% and a 3-year survival rate of 
4% vs 0% [40]. 
The majority of AEs were lower-grade, with higher rates in patients receiv-
ing nab-paclitaxel plus gemcitabine. In terms of SAEs and AEs leading to 
death, there was no statistically significant difference between the groups 
reported. Most frequent AEs of grade 3 or higher were neutropenia, leuko-
penia and fatigue. Beside these, it has to be pointed out that more than 50% 
of the patients in the intervention group developed a peripheral neuropathy, 
with 17% of them being of grade ≥ 3. In the control group, this grade ≥ 3 
AE was present in only 1% of the patients. Although this adverse reaction 
seems to be reversible after suspension of nab-paclitaxel, the median time to 
improvement from grade 3 peripheral neuropathy to grade ≤1 was 29 days 
in the study, which is about half of the period of OS improvement. 
Despite the results of the MPACT trial, some limitations occur for the 
treatment with nab-paclitaxel in patients with metastatic pancreas carcino-
ma. In the study population a proportion of 92% had good performance sta-
tus with a Karnofsky status score of 80 and higher [26]. In addition, this 
study included only patients with a bilirubin level within the normal rage. 
Data for patients with an increased bilirubin level causing jaundice, which 
is present in 56% of all patients with pancreatic cancer [44], are not availa-
ble. So the effect of a combination of nab-paclitaxel and gemcitabine cannot 
be directly translated to the general population of patients with metastatic 
pancreas carcinoma, for whom it is approved. 
Improving quality of life (QoL) is an important aim for any cancer therapy 
and is urgently needed, especially when it comes to therapeutic decision-
making in the palliative setting. While for instance a recent study compar-
ing FOLFIRINOX to gemcitabine provided data on QoL showing a signifi-
cant delay in its deterioration, the current study did neither include a meas-
urement of patients’ quality of life nor of the change in cancer symptoms. 
In addition, the MPACT trial only addresses the question of safety and effi-
cacy of nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients 
with metastatic pancreas carcinoma, which was standard chemotherapy at 
the start of the trial in 2009. Looking at recent guidelines for pancreatic car-
cinoma, gemcitabine monotherapy is a treatment option for patients with 
metastatic disease and poor performance status but also for patients not eli-
gible for more intensive therapy due to other factors (e.g. age or abnormal 
bilirubin level). For patients with ECOG performance status 0 or 1 and a 
bilirubin level within or slightly above the normal range, a combination 
chemotherapy is preferred [23, 25]. Therefore, from the present point of 
view, treatment with gemcitabine alone may not be an appropriate compara-
tor for the examined patient group. To date, there is no study investigating 
the benefits and harms of nab-paclitaxel plus gemcitabine in comparison to 
one RCT comparing nab-
paclitaxel + gemcitabine 
vs gemcitabine alone 
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other standard-of-care options for patients with good performance status, 
such as FOLFIRINOX. Such studies might be relevant for a treatment deci-
sion, especially since an indirect comparison between data from the MPACT 
trial for nab-paclitaxel plus gemcitabine and data from a FOLFIRINOX 
study showed slightly better results for FOLFIRINOX [45].  
Compared to standard chemotherapy with gemcitabine alone, the costs per 
treatment cycle for nab-paclitaxel plus gemcitabine are about 2 times high-
er, but this might be different when compared to the costs of recently rec-
ommended combination chemotherapies. Since nab-paclitaxel in combina-
tion with gemcitabine is only recommended for metastatic pancreas carci-
noma and good performance status affecting only a small group of patients, 
there will probably be no major budget impact at the moment. However, the 
impact will increase if the treatment indication is extended to earlier tu-
mour stages or different treatment settings (e.g. adjuvant therapy) which are 
under investigation in several studies.  
Therapeutic options for metastatic pancreatic carcinoma are limited. The 
regulatory approval by the FDA and the European Commission for nab-
paclitaxel in combination with gemcitabine means that a new therapy is now 
available which has demonstrated an increase in PFS and OS in patients 
with a good performance status and a bilirubin level within the normal 
range. This combination may be a treatment option, especially for patients 
who may not be eligible for FOLFIRINOX, e.g. people older than 75 years of 
age. Nevertheless, this treatment is also associated with higher rates of ad-
verse events, especially a strongly increased rate of peripheral neuropathy. 
  
Besides data on survival and costs, differences in toxicity profiles and ease of 
administration as well as the patients’ preferences are aspects that should be 
considered in deciding on the recommended combination therapies. As data 
on QoL for nab-paclitaxel plus gemcitabine are missing and as there are no 
studies comparing this treatment regimen to the other recommended com-
bination chemotherapy (i.e. FOLFIRINOX), many unresolved questions 
still remain. 
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